InTrOduCTIOn
There are several options available for treating symptomatic infants with tetralogy of Fallot (ToF), including primary surgical repair (PrR), palliation with a systemic-to-pulmonary (SPS) shunt and the more recent palliation by right ventricular outflow tract or pulmonary valve dilation (RVOTd), with ductal stenting being less frequent.
Before the improvement in surgical techniques, perioperative care and the advent of transcatheter palliation procedures, the preferred treatment for symptomatic infants was an early SPS and then an elective secondary complete repair (ScR) subsequently. Data emerging on high mortality and complication rates following neonatal SPS 1 have led to alternative options to be explored, with early PrR (before 3 months) and transcatheter palliation gaining traction. 2 Currently there is no consensus regarding the best strategy, with reports of good results with both early or neonatal repair, 3 4 RVOTd 5 and even SPS. 2 We have previously shown that among all lesions with pulmonary obstruction, ToF had the lowest mortality after SPS palliation, with fewer such procedures being performed in these patients each year, likely due to better patient selection. 6 At the same time, all options have disadvantages: early PrR can increase the need for a transannular patch and late morbidity, SPS has high rates of complications while RVOTd is associated with valve lesions and reinterventions. 2 There are only a few studies directly comparing these management strategies, but with inherent differences among the compared groups, since each centre will have different practices. 3 5 There is a need for a direct comparative study with sufficient data to allow for adjusting for these differences. A national registry can offer both the large population and the good quality data required for such a study.
The National Congenital Heart Disease Audit (NCHDA) collects data on all cardiac procedures performed for congenital heart disease in the United Kingdom. In this study we aim to: 1) describe contemporary practice and trends; 2) compare PrR, SPS palliation and RVOTd outcomes in matched groups; and, 3) identify predictors of outcomes after these treatments.
MeThOds

Patient selection and classification
National data collection has been previously described. 6 All but 4 (0.2%) of patients in the final dataset have survival data. Data on 5616 patients with ToF treated between 2000-2013 were available. We excluded the following patients: 2084 born before the registry was created, therefore without complete procedural history, 871 aged over 1 year at first procedure, 489 from overseas, Scotland or Ireland, 332 with other complex cardiac defects (transposition of great arteries, corrected transposition of great arteries, double outlet right ventricle, complete atrioventricular septal defect, double chambered right ventricle, cor triatriatum, total anomalous pulmonary connection, single ventricle morphology, ventricle imbalance, isomerism, pulmonary valve atresia, tricuspid atresia, mitral atresia), 37 with major aorto-pulmonary collateral arteries, 118 with miscellaneous data errors (empty data fields, diagnosis/procedure code errors), and 23 with other initial procedures than those of interest. This resulted in 1662 patients undergoing 2364 procedures including reinterventions -pulmonary valve replacements (PVR), SPS, pulmonary artery (PA) or right ventricular outflow tract (RVOT) reinterventions.
statistical analyses
Frequencies are given as absolute numbers and percentages, continuous values as median (inter-quartile range). Short term outcomes are calculated based on 30 day data. Population characteristics were compared using the Mann-Whitney, Student-t and the Fisher exact tests.
Estimates of long term outcomes are made with the KaplanMeier method using mortality (all cause) and reintervention (any, SPS, RVOT non PVR, PA and PVR), calculated before repair (for SPS and RVOTd), after repair and for the full follow-up (for all three groups, from first procedure to end). Rates of next event (online supplementary table IV) are estimated using the data obtained after applying the modulated renewal approach. 6 When considering reintervention outcomes by type, surgical and transcatheter procedures of the same nature were considered as one event type (RVOT and PA reinterventions respectively); PVR with and without PA repair was also grouped as one reintervention type (PVR). This was done to maintain simplicity, on the premise that reinterventions in the same group were performed under similar indications.
We conducted three additional analyses: pairwise three-way comparisons of procedures, and predictive models for each of the three procedure types. Matching was done using a stochastic augmentation with restriction methods (SAMUR package for R). 7 8 For both survival analysis after matching and the three predictive models, a Bayesian survival analysis using generalised Weibull approach was used (BSGW package for R). 9 To look at the effect of reinterventions in the predictive models, a modulated renewal approach was used. 6 Detailed statistical methods can be found in the online supplementary material.
Statistical analyses were done with STATA/IC 11.2 (StataCorp LP, College Station, TX) and R version 3.1 (R Core Team, 2015) .
resulTs
A total of 1662 infants with ToF were included, with a median age of 181 (101-257) days, undergoing primary surgical repair (n=1244), SPS (n=311) or RVOTd (n=107) between 2000 and 2013, from 12 centres (mean patients/centre 156, range 6-281). There was a trend for fewer SPS procedures and more PrRs and RVOTd observed during this period (figure 1).
Demographic, clinical and procedural data, regarding the initial procedure can be seen in table 1; data on ScR and reinterventions are shown in the online supplementary table I. Of note are the significant differences in population characteristics, especially age and weight. A schematic of the treatment pathways is presented in figure 2 .
By plotting survival curves in 30 day increments we found that mortality at 12 years is higher when repair or palliation is performed before the age of 60 days rather than after, most significantly for PrR (18.7% vs 2.2% after, P<0.001), less so for RVOTd (10 Due to the significant differences in patient characteristics among the three groups of interest, we proceeded to perform matched-groups analyses.
sPs versus rVOTd
Patients with SPS and RVOTd were matched in a pairwise comparison. Differences in groups before and after matching are detailed in online supplementary table V.
RVOTd was associated with more RVOT (non-PVR) pre-repair reinterventions when compared with the SPS (P=0.001, figure 3A ). Post-repair outcomes did not differ significantly. This results in more overall reinterventions from initial palliation to follow-up after repair in the RVOTd group (P=0.01). Before and after matching comparison data are detailed in table 2 and online supplementary table VI. There were more complete repairs with transannular patches in the RVOTd group, with a similar proportion before and after matching (68% vs 53%, P=0.01 before, 68% vs 54%, P=0.07 after).
Congenital heart disease
Prr versus sPs versus rVOTd
Patients in the PrR, SPS and RVOTd groups were matched in a three-way comparison. Differences in groups before and after matching are detailed in online supplementary table VII. RVOTd was associated with more RVOT (non PVR) reinterventions (P=0.04, figure 3B ) from initial procedure onward. We found fewer PVRs overall in the SPS and RVOTd groups compared with PrR (P=0.05 and 0.06 respectively, figure 3C), with slightly fewer deaths after repair in the RVOTd group (P=0.09 versus PrR, figure 3D ); all three associations were borderline statistically significant and not observed in the unmatched groups. Before and after matching comparison data are detailed in table 3 and online supplementary table VIII. There were fewer complete repairs using a transannular patch in the PrR group, when compared with SPS and RVOTd respectively, both before matching (42% vs 47 vs 47%, P<0.001) and after matching (43% vs 55% vs 68%, P=0.003).
Predictors of outcomes
In addition to the comparison of possible treatment options, a multivariable analysis was performed for each main group separately, taking into consideration the subsequent procedures. We found that outcomes after PrR and palliation in infants with ToF are influenced by a vast array of factors, both patient related and procedure related. See online supplementary table IX shows all identified predictors. 
dIsCussIOn
Both primary repair and palliation in ToF are associated with higher mortality when performed before the age of 60 days, but the differences appear to be more significant when the choice is primary repair (more than eight times higher). After matching was performed in all three options, thus selecting the youngest, highest risk infants, those undergoing initial RVOTd have more RVOT (non-PVR) reinterventions when compared with PrR, fewer PVRs and also fewer long term deaths, the latter not reaching statistical significance. These findings, although retrospective, suggest that in those infants under the age of 60 days palliation might offer better outcomes when compared with primary repair. Even so, there were numerous factors influencing the outcomes in each group, from patient age and size, to associated conditions, need for reinterventions and even procedure era.
In the UK, as in most countries, the management of ToF varies between institutions. 10 The same patient might undergo palliation by SPS in one unit, RVOTd in another or PrR in the next, with no consensus on patient selection. No option is without its critics -early PrR might be associated with increased late morbidity due to use of transannular patching, SPSs have garnered a bad reputation due to complications, while RVOTd has yet to be adopted in all centres. 2 11 This is, to our knowledge, the first study to directly compare all three commonly used treatment options, while also adjusting for some confounding differences. Previous studies comparing PrR to one palliation method or another 3 5 acknowledged procedural selection bias. By including all patients in a large geographical area we could compare patients which would potentially be candidates for all three options.
Congenital heart disease
Comparing palliation options
Current palliation options are SPS, RVOTd and ductal stenting, the latter being rarely used for ToF in the UK. RVOT dilation or stenting is usually chosen in babies with risk factors for surgery who tend to be smaller and sicker, 5 12 which is also true in our study. We found significantly more RVOT (non-PVR) reinterventions in the RVOTd group, the differences being observed only in the pre-repair period. We assume that even after matching, those in the RVOTd group would still represent a population with surgical risk factors, and as such the true benefits of the transcathateter approach might be underestimated. As such RVOTd could be a comparable, if not superior, alternative to SPS palliation in similar patients.
Comparing all three options
There are situations when the decision to do a complete repair or a palliation in an infant depends on the centre practice. This is also true for neonates, even if there is considerable debate on whether the low early mortality is at the expense of long term morbidity. 2 There are few data on how these treatment options fare head-to-head, with no reports comparing all three simultaneously.
At a glance, looking at the whole population of unmatched infants with ToF, PrR appears to have significantly better outcomes when compared with both palliation options. Such a comparison is misleading, as many times patients differ greatlyin our cohort those referred for palliation were younger, smaller, had poorer growth for age and more genetic conditions. The differences observed in an uninformed comparison can be due to treatment selection and not the procedures themselves. Having data from consecutive patients in 12 centres allowed us to limit the three-way comparison to groups with similar characteristics in terms of age, weight, somatic development and associated abnormalities; we aimed to include only patients who could have been selected in theory for any of the three options.
In this matched analysis all three treatments achieved somewhat comparable results, but with a few notable differences. There were more RVOT (non-PVR) reinterventions in the RVOTd group as found in previous studies, 3 5 but without an increase in mortality and PVR. Interestingly, we observed an overall lower risk of PVR in both palliation groups when compared with PrR, not just in one or the other, even if there were more secondary repairs using a transannular patch. In our study more than two thirds of the RVOTd procedures did not employ a stent, which would explain the much lower proportion of transannular patching (47% before matching, 68% after matching compared with 82% reported by Wilder et al and 100% by Sandoval et al, the latter using only stenting). 5 10 Quandt et al describe a large single centre experience with RVOT stenting in a variety of lesions, transannular patch usage being comparable to SPS. 12 In our study we observed that using a balloon rather than a stent increases the risk of SPS placement afterwards due to inadequate pulmonary blood flow. Whether a palliation strategy using repeat balloon dilation rather than stenting, in an effort to preserve the valve, is preferable is still to be determined.
Previous reports described a high incidence of PA reinterventions after RVOTd. 5 After matching we found similar PA reintervention rates in all three groups. More PA reinterventions were observed in the SPS and RVOTd groups only in overall, unmatched comparisons. This suggests that the differences previously described are more likely due to infants with less developed PA branches being referred more frequently to palliation rather than PrR. During follow-up the somatic growth of the PA branches 'catches up' in these groups, which further support this conclusion.
5
Predictors of outcomes after Prr
To our knowledge this is the largest group of unselected consecutive infants with ToF undergoing PrR reported to date. This allowed for a complex analysis, including the influence of reinterventions on subsequent events.
The most discussed aspect of primary repair is age. There is no definitive age of 'optimal' repair, and one might not be identified due to the large number of confounding factors. In our data when looking at age increments of 30 days, we found a steep drop in late mortality when primary repair was performed after age 60 days (from 18.7% before 60 days to 2.2% after).
In our study worse outcomes were associated with characteristics found in those patients with underdeveloped RVOTs and PAs, like smaller age, smaller weight for age (z-score), use of transannular patching, need for PA procedures at index or afterwards and genetic syndromes. Using a palliation method to allow for more somatic growth appears to be a preferable option, as both palliation methods appear to be comparable to PrR in these patients. Our finding, that using a transannular patch is associated with both increased mortality and future need for PVR, supports other data suggesting that a key aspect of repair is preserving the pulmonary valve when possible. 5 It is reassuring that reinterventions in the first 10 years after ToF repair are not associated with increased mortality, only with further subsequent reinterventions. Also, procedures performed in recent years have had a steadily decreasing mortality and PVR rate. Surgical PA repair at index is associated with increased mortality and a higher risk for further PA reinterventions. Additionally, PA reinterventions themselves, surgical or transcatheter, increase the chance for future such reinterventions. Wilder et al concluded that aggressive patch augmentation for hypoplastic branch PAs might increase the reintervention rates, and suggest that after repair or palliation PA branches should develop well enough without further instrumentation. 13 Finding these associations between PA interventions and poorer outcomes in our multivariable models supports the notion that somatic growth rather than surgical patching should be preferred, when possible. PA arterioplasty performed at the time of PrR is associated with increased mortality, but not when done as a reintervention later on. This suggests that that allowing the PAs to grow before intervening might be the better option.
Predictors of outcomes after sPs
We found that smaller age and weight for age at SPS placement are associated with increased mortality, a well-documented fact. 1 6 PA repair, both at index and as a reintervention, is associated with more PA procedures, as was the case for PrR, further supporting the conclusion that patching the pulmonary arteries instead of allowing for somatic growth might lead to poorer outcomes. This conclusion warrants further research.
Predictors of outcomes after rVOT transcatheter palliation
In multivariable analysis we did not identify any predictors of increased early mortality, but under the limitation of just seven deaths. Taking into consideration that all deaths occurred in patients under 60 days, we can speculate that this age category remains a challenge, regardless of treatment. It is reassuring that RVOTd patients did not have a higher mortality compared with SPS and PrR, supporting the notion that RVOTd is an option in challenging cases when other methods are not feasible. 5 12 Patients with small age, genetic syndromes or where only a balloon dilation was used were at an increased risk for requiring further palliation by SPS placement. It is possible that the clinical scenario resulted in insufficient pulmonary flow, and an alternative palliation was used. The presence of a right aortic arch was strongly associated with SPS placements after RVOTd; this might be a spurious result, possibly confounded by surgical anatomy. In more recent years fewer SPS placements after RVOTd were observed, in the general context of SPS usage dropping in the UK.
limitations
The study is limited by absence of clinical data such as severity of symptoms, imaging, and the relatively short follow-up. It also has limitations inherent to a retrospective design, including the matching methods. In the three-way comparison, to balance the resulting groups' size and the matching quality, some subgroup differences remain. Finally, neonatal primary repair is uncommon in the UK so our study offers little information regarding this option.
COnClusIOns
The UK database offered a unique insight into how the treatment options for infants with ToF compare. We found that RVOTd was associated with more RVOT reinterventions, fewer PVR and potentially fewer deaths when compared with PrR in young infants, especially so in those under 60 days at the time of the first procedure. The role of primary repair and SPS in this high-risk group needs to be reevaluated, as is the use of transannular patching.
Contributors D Dorobantu -data analysis, study design, statistical analysis, manuscript writing. a Mahani, M sharabiani -statistical analysis, manuscript writing. r Pandey -study design, manuscript writing, data interpretation. g angelini -study design, manuscript writing, data interpretation. a Parry -study design, manuscript writing. r tulloh -manuscript writing, data interpretation. r Martin -manuscript writing, data interpretation. s stoica -study design, manuscript writing, data interpretation, overseeing of the project.
Funding this research was supported by national institute for health research (nihr) Bristol cardiovascular Biomedical research Unit, the British heart Foundation (grant number ch/1992027/7163) and used data provided by the national institute for cardiovascular Outcomes research, as part of the national congenital heart Disease audit (nchDa). the nchDa is commissioned by the healthcare Quality improvement Partnership (hQiP) as part of the national clinical audit and Patient Outcomes Programme (ncaPOP) and within the national health service, United Kingdom.
disclaimer the views expressed are those of the authors and not necessarily those of the national health service, nihr, or Department of health.
Competing interests none declared.
Patient consent not required.
ethics approval national institute for cardiovascular Outcomes research.
Provenance and peer review not commissioned; externally peer reviewed. data sharing statement there is no unpublished data relevant to this study.
